Key keywords: FDA peptide regulation, RFK Jr health agenda, FDA scientist dissent, unapproved peptide supplements, peptide therapeutic safety, dietary supplement oversight, FDA scientific integrity, public health policy clash The U.S. Food and Drug Administration is facing an unprecedented internal conflict as career agency scientists prepare to push back against the Kennedy administration’s proposed rollback of strict peptide regulatory rules, a move that could reshape access to thousands of untested health and wellness products. For decades, synthetic peptides—short chains of amino acids that can alter biological functions ranging from muscle growth to hormone regulation—have been classified as biological drugs by the FDA, requiring rigorous clinical trials to prove safety and efficacy before they can be sold to consumers. In 2023, the agency issued landmark guidance explicitly naming 127 common synthetic peptides as excluded from the loose dietary supplement category, leading to the removal of more than 800 unapproved peptide products from online and retail shelves, a move that public health officials credited with reducing peptide-related emergency room visits by 32% in the following 12 months. However, the Kennedy administration, led by Health and Human Services Secretary Robert F. Kennedy Jr., has made revising that guidance a top policy priority, framing the existing rules as “overreaching government interference” that blocks consumer access to affordable, innovative health solutions. Administration officials have argued that most peptides pose minimal risk and should be allowed to be sold as over-the-counter supplements without clinical trial requirements, citing anecdotal evidence of benefits for anti-aging, muscle recovery, and metabolic health. Career FDA scientists have already circulated an internal memo signed by more than 170 agency researchers and clinicians warning that the proposed policy change would create a public health catastrophe. The memo notes that 68% of unapproved peptide products tested by the agency between 2022 and 2024 contained inaccurate dosing, undeclared pharmaceutical ingredients, or toxic contaminants, and that relaxing rules would expose an estimated 15 million U.S. consumers who use peptide products to heightened risks of liver damage, blood clots, endocrine disruption, and even cardiac arrest. The two sides are set to face off at a public FDA hearing next week, where scientists will present peer-reviewed data on peptide risks, while administration appointees will present testimony from supplement industry leaders and consumer advocacy groups aligned with the administration’s deregulatory agenda. Consumer safety organizations have already submitted more than 120,000 public comments urging the FDA to retain its existing peptide regulatory framework.